Results 31 to 40 of about 152,172 (364)

RSV disease in infants and young children: Can we see a brighter future?

Human Vaccines & Immunotherapeutics, 2022
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations
Eugenio Baraldi, Giovanni Checcucci Lisi, Claudio Costantino, Jon H. Heinrichs, Paolo Manzoni, Matteo Riccò, Michelle Roberts, Natalya Vassilouthis   +7 more
doaj   +1 more source

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

Journal of Infectious Diseases, 2022
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for ...
A. Kieffer, Matthieu Beuvelet, A. Sardesai, Robert Musci, S. Milev, J. Roiz, Jason K H Lee   +6 more
semanticscholar   +1 more source

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein

Viruses, 2022
It is important to understand the features affecting virus replication, fitness, and transmissibility as they contribute to the outcome of infection and affect disease intervention approaches. Respiratory syncytial virus (RSV) is a major contributor to respiratory disease, particularly in the infant and elderly populations.
Harrison C. Bergeron, Ralph A. Tripp
openaire   +3 more sources

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.

Cochrane Database of Systematic Reviews, 2021
BACKGROUND Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population.
L. Garegnani, Lea Styrmisdóttir, P. Roson Rodriguez, C. E. Escobar Liquitay, I. Esteban, Juan V A Franco   +5 more
semanticscholar   +1 more source

Is it RSV? [PDF]

Health Science Reports, 2018
A study of infant bronchiolitis–coded episodes described the proportion of events attributable to respiratory syncytial virus (RSV) and demonstrated that episodes occurring during the peak months of winter viral season, among younger infants, and among those with higher levels of care, were more likely to be attributable to RSV.
openaire   +3 more sources

Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano

Farmeconomia: Health Economics and Therapeutic Pathways, 2011
Palivizumab is a monoclonal antibody to RSV that has been shown to significantly reduce the frequency of hospitalisations for RSV infection, in at-risk populations. However, payers are concerned about the budgetary impact of adopting palivizumab.
Daniela Roggeri
doaj   +1 more source

DYNAMICS OF CHILDHOOD RESPIRATORY INFECTIONS DURING THE COVID-19 PANDEMIC: THE EFFECT OF QUARANTINE АND BEYOND

Central Asian Journal of Medical Hypotheses and Ethics, 2021
Monitoring epidemic processes and the dynamics of the spread of infectious diseases is essential for predicting their distribution and effective planning in healthcare.
Snezhina Lazova, Tsvetelina Velikova
doaj   +1 more source

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state [PDF]

, 2017
Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral membrane protein that is essential for infection.
Chen, Man, Gilman, Morgan SA, Graham, Barney S, Kabeche, Stephanie C, Kanekiyo, Masaru, Mas, Vicente, McLellan, Jason S, Melero, José A, Rossey, Iebe, Saelens, Xavier, Schepens, Bert, Sedeyn, Koen, Spitaels, Jan, Wrapp, Daniel   +13 more
core   +2 more sources

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.

New England Journal of Medicine, 2020
BACKGROUND Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants.
M. P. Griffin, Yuan Yuan, Therese Takas, J. Domachowske, S. Madhi, P. Manzoni, E. Simões, M. Esser, Anis A. Khan, F. Dubovsky, T. Villafana, J. DeVincenzo   +11 more
semanticscholar   +1 more source

Reducing respiratory syncytial virus (RSV) hospitalization in a lower-income country by vaccinating mothers-to-be and their households [PDF]

, 2019
Respiratory syncytial virus is the leading cause of lower respiratory tract infection among infants. RSV is a priority for vaccine development. In this study, we investigate the potential effectiveness of a two-vaccine strategy aimed at mothers-to-be ...
Agoti, Anderson, Anderson, Atkins, Ball, Bhattacharyya, Brand, Chin, Cohen, Dempster, Diekmann, Domachowske, Geard, Glass, Glezen, Graham, Grimmett, Hall, Hall, Hall, Hall, Henderson, Hinch, Hogan, House, House, Keeling, Keeling, King, Kinyanjui, Kinyanjui, Kiti, KNBS, Kurtz, Kurtz, Miller, Modjarrad, Moore, Mossong, Munywoki, Nair, Nokes, Nokes, NovaVax, Ohuma, O’Neill, Pan-Ngum, PATH, Paynter, Paynter, Pitzer, Poletti, Prem, Rackauckas, Rock, Scott, Scott, Storn, Sun, White, White, World Health Organization, Yamin, Zhu   +63 more
core   +1 more source